APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Transthyretin Amyloid Cardiomyopathy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Outlook and Growth Opportunities 2026

27 December 2025192 pages

Choose your research edition.

Industry ResearchDrugs for Transthyretin Amyloid Cardiomyopathy Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Transthyretin Amyloid Cardiomyopathy Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Drugs for Transthyretin Amyloid Cardiomyopathy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Transthyretin Amyloid Cardiomyopathy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Transthyretin Amyloid Cardiomyopathy Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Drugs for Transthyretin Amyloid Cardiomyopathy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Transthyretin Amyloid Cardiomyopathy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Transthyretin Amyloid Cardiomyopathy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Transthyretin Amyloid Cardiomyopathy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Transthyretin Amyloid Cardiomyopathy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Transthyretin Amyloid Cardiomyopathy market include Chia Tai Tianqing Pharmaceutical, Tonghua Zhongsheng Pharmaceutical, Zhengzhou Taifeng Pharmaceutical, Shapuaisi Pharma, Qilu pharmaceutical, Luoxin Pharmaceutical, Zydus Pharms, Teva and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for Transthyretin Amyloid Cardiomyopathy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Transthyretin Amyloid Cardiomyopathy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Transthyretin Amyloid Cardiomyopathy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Transthyretin Amyloid Cardiomyopathy market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Company

Chia Tai Tianqing Pharmaceutical

Tonghua Zhongsheng Pharmaceutical

Zhengzhou Taifeng Pharmaceutical

Shapuaisi Pharma

Qilu pharmaceutical

Luoxin Pharmaceutical

Zydus Pharms

Teva

Pfizer

Ionis Pharmaceuticals

Avet Pharmaceuticals

Alnylam Pharmaceuticals

Akcea Therapeutics

Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Type

RNA Interference

Antisense Oligonucleotides

Transthyretin Tetramer Stabilizer

Other

Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Transthyretin Amyloid Cardiomyopathy status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs for Transthyretin Amyloid Cardiomyopathy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Transthyretin Amyloid Cardiomyopathy significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Transthyretin Amyloid Cardiomyopathy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Transthyretin Amyloid Cardiomyopathy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Transthyretin Amyloid Cardiomyopathy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Transthyretin Amyloid Cardiomyopathy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Transthyretin Amyloid Cardiomyopathy market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Transthyretin Amyloid Cardiomyopathy industry.

Chapter 3: Detailed analysis of Drugs for Transthyretin Amyloid Cardiomyopathy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs for Transthyretin Amyloid Cardiomyopathy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs for Transthyretin Amyloid Cardiomyopathy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Transthyretin Amyloid Cardiomyopathy Industry Trends Table 2. Drugs for Transthyretin Amyloid Cardiomyopathy Industry Drivers Table 3. Drugs for Transthyretin Amyloid Cardiomyopathy Industry Opportunities and Challenges Table 4. Drugs for Transthyretin Amyloid Cardiomyopathy Industry Restraints Table 5. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Company (2021-2026) Table 7. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share by Company (2021-2026) Table 9. Global Drugs for Transthyretin Amyloid Cardiomyopathy Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Drugs for Transthyretin Amyloid Cardiomyopathy Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs for Transthyretin Amyloid Cardiomyopathy Key Company Manufacturing Base & Headquarters Table 12. Global Drugs for Transthyretin Amyloid Cardiomyopathy Company, Product Type & Application Table 13. Global Drugs for Transthyretin Amyloid Cardiomyopathy Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Transthyretin Amyloid Cardiomyopathy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of RNA Interference Table 18. Significant Companies of Antisense Oligonucleotides Table 19. Significant Companies of Transthyretin Tetramer Stabilizer Table 20. Significant Companies of Other Table 21. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share by Type (2021-2026) Table 25. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share by Type (2027-2032) Table 26. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type (2021-2026) Table 30. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Retail Pharmacies Table 32. Significant Companies of Hospital and Clinic Table 33. Significant Companies of Other Table 34. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share by Application (2021-2026) Table 38. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share by Application (2027-2032) Table 39. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application (2021-2026) Table 43. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application (2027-2032) Table 44. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2021-2026) & (K Units) Table 46. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2021-2026) Table 47. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2027-2032) & (K Units) Table 48. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2027-2032) Table 49. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Region (2021-2026) Table 52. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Region (2027-2032) Table 54. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021-2026) & (K Units) Table 59. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2021-2026) Table 60. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2027-2032) & (K Units) Table 61. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2027-2032) Table 62. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Market Share by Country (2021-2026) Table 64. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Market Share by Country (2027-2032) Table 66. Chia Tai Tianqing Pharmaceutical Company Information Table 67. Chia Tai Tianqing Pharmaceutical Business Overview Table 68. Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 70. Chia Tai Tianqing Pharmaceutical Recent Development Table 71. Tonghua Zhongsheng Pharmaceutical Company Information Table 72. Tonghua Zhongsheng Pharmaceutical Business Overview Table 73. Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 75. Tonghua Zhongsheng Pharmaceutical Recent Development Table 76. Zhengzhou Taifeng Pharmaceutical Company Information Table 77. Zhengzhou Taifeng Pharmaceutical Business Overview Table 78. Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 80. Zhengzhou Taifeng Pharmaceutical Recent Development Table 81. Shapuaisi Pharma Company Information Table 82. Shapuaisi Pharma Business Overview Table 83. Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 85. Shapuaisi Pharma Recent Development Table 86. Qilu pharmaceutical Company Information Table 87. Qilu pharmaceutical Business Overview Table 88. Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 90. Qilu pharmaceutical Recent Development Table 91. Luoxin Pharmaceutical Company Information Table 92. Luoxin Pharmaceutical Business Overview Table 93. Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 95. Luoxin Pharmaceutical Recent Development Table 96. Zydus Pharms Company Information Table 97. Zydus Pharms Business Overview Table 98. Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 100. Zydus Pharms Recent Development Table 101. Teva Company Information Table 102. Teva Business Overview Table 103. Teva Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Teva Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 105. Teva Recent Development Table 106. Pfizer Company Information Table 107. Pfizer Business Overview Table 108. Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 110. Pfizer Recent Development Table 111. Ionis Pharmaceuticals Company Information Table 112. Ionis Pharmaceuticals Business Overview Table 113. Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 115. Ionis Pharmaceuticals Recent Development Table 116. Avet Pharmaceuticals Company Information Table 117. Avet Pharmaceuticals Business Overview Table 118. Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 120. Avet Pharmaceuticals Recent Development Table 121. Alnylam Pharmaceuticals Company Information Table 122. Alnylam Pharmaceuticals Business Overview Table 123. Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 125. Alnylam Pharmaceuticals Recent Development Table 126. Akcea Therapeutics Company Information Table 127. Akcea Therapeutics Business Overview Table 128. Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 130. Akcea Therapeutics Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Drugs for Transthyretin Amyloid Cardiomyopathy Distributors List Table 134. Drugs for Transthyretin Amyloid Cardiomyopathy Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Drugs for Transthyretin Amyloid Cardiomyopathy Product Image Figure 2. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales (2021-2032) & (K Units) Figure 5. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Drugs for Transthyretin Amyloid Cardiomyopathy Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. RNA Interference Image Figure 10. Antisense Oligonucleotides Image Figure 11. Transthyretin Tetramer Stabilizer Image Figure 12. Other Image Figure 13. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share by Type (2021-2032) Figure 16. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type (2021-2032) Figure 19. Retail Pharmacies Image Figure 20. Hospital and Clinic Image Figure 21. Other Image Figure 22. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share by Application (2021-2032) Figure 25. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application (2021-2032) Figure 28. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032) & (US$ Million) Figure 33. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032) & (US$ Million) Figure 39. South America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Drugs for Transthyretin Amyloid Cardiomyopathy Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Drugs for Transthyretin Amyloid Cardiomyopathy Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • RNA Interference
  • Antisense Oligonucleotides
  • Transthyretin Tetramer Stabilizer
  • Other
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Tonghua Zhongsheng Pharmaceutical
  • Zhengzhou Taifeng Pharmaceutical
  • Shapuaisi Pharma
  • Qilu pharmaceutical
  • Luoxin Pharmaceutical
  • Zydus Pharms
  • Teva
  • Pfizer
  • Ionis Pharmaceuticals
  • Avet Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032)
  4. 1.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs for Transthyretin Amyloid Cardiomyopathy Market Dynamics
  1. 2.1 Drugs for Transthyretin Amyloid Cardiomyopathy Industry Trends
  2. 2.2 Drugs for Transthyretin Amyloid Cardiomyopathy Industry Drivers
  3. 2.3 Drugs for Transthyretin Amyloid Cardiomyopathy Industry Opportunities and Challenges
  4. 2.4 Drugs for Transthyretin Amyloid Cardiomyopathy Industry Restraints
3 Drugs for Transthyretin Amyloid Cardiomyopathy Market by Company
  1. 3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs for Transthyretin Amyloid Cardiomyopathy Average Price by Company (2021-2026)
  5. 3.5 Global Drugs for Transthyretin Amyloid Cardiomyopathy Company Ranking (2024-2026)
  6. 3.6 Global Drugs for Transthyretin Amyloid Cardiomyopathy Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs for Transthyretin Amyloid Cardiomyopathy Company Product Type and Application
  8. 3.8 Global Drugs for Transthyretin Amyloid Cardiomyopathy Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs for Transthyretin Amyloid Cardiomyopathy Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs for Transthyretin Amyloid Cardiomyopathy Market by Type
  1. 4.1 Drugs for Transthyretin Amyloid Cardiomyopathy Type Introduction
  2. 4.1.1 RNA Interference
  3. 4.1.2 Antisense Oligonucleotides
  4. 4.1.3 Transthyretin Tetramer Stabilizer
  5. 4.1.4 Other
  6. 4.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Type
  7. 4.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Type
  11. 4.3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Type (2021-2032)
  13. 4.3.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type (2021-2032)
5 Drugs for Transthyretin Amyloid Cardiomyopathy Market by Application
  1. 5.1 Drugs for Transthyretin Amyloid Cardiomyopathy Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital and Clinic
  4. 5.1.3 Other
  5. 5.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Application
  6. 5.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Application
  10. 5.3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Application (2021-2032)
  12. 5.3.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application (2021-2032)
6 Drugs for Transthyretin Amyloid Cardiomyopathy Regional Sales and Value Analysis
  1. 6.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2027-2032)
  5. 6.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032)
  12. 6.6.2 North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032)
  21. 6.9.2 South America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Country, 2025 VS 2032
7 Drugs for Transthyretin Amyloid Cardiomyopathy Country-level Sales and Value Analysis
  1. 7.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2027-2032)
  6. 7.4 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs for Transthyretin Amyloid Cardiomyopathy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Tonghua Zhongsheng Pharmaceutical
  8. 8.2.1 Tonghua Zhongsheng Pharmaceutical Company Information
  9. 8.2.2 Tonghua Zhongsheng Pharmaceutical Business Overview
  10. 8.2.3 Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  12. 8.2.5 Tonghua Zhongsheng Pharmaceutical Recent Developments
  13. 8.3 Zhengzhou Taifeng Pharmaceutical
  14. 8.3.1 Zhengzhou Taifeng Pharmaceutical Company Information
  15. 8.3.2 Zhengzhou Taifeng Pharmaceutical Business Overview
  16. 8.3.3 Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  18. 8.3.5 Zhengzhou Taifeng Pharmaceutical Recent Developments
  19. 8.4 Shapuaisi Pharma
  20. 8.4.1 Shapuaisi Pharma Company Information
  21. 8.4.2 Shapuaisi Pharma Business Overview
  22. 8.4.3 Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  24. 8.4.5 Shapuaisi Pharma Recent Developments
  25. 8.5 Qilu pharmaceutical
  26. 8.5.1 Qilu pharmaceutical Company Information
  27. 8.5.2 Qilu pharmaceutical Business Overview
  28. 8.5.3 Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  30. 8.5.5 Qilu pharmaceutical Recent Developments
  31. 8.6 Luoxin Pharmaceutical
  32. 8.6.1 Luoxin Pharmaceutical Company Information
  33. 8.6.2 Luoxin Pharmaceutical Business Overview
  34. 8.6.3 Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  36. 8.6.5 Luoxin Pharmaceutical Recent Developments
  37. 8.7 Zydus Pharms
  38. 8.7.1 Zydus Pharms Company Information
  39. 8.7.2 Zydus Pharms Business Overview
  40. 8.7.3 Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  42. 8.7.5 Zydus Pharms Recent Developments
  43. 8.8 Teva
  44. 8.8.1 Teva Company Information
  45. 8.8.2 Teva Business Overview
  46. 8.8.3 Teva Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Teva Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  48. 8.8.5 Teva Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Ionis Pharmaceuticals
  56. 8.10.1 Ionis Pharmaceuticals Company Information
  57. 8.10.2 Ionis Pharmaceuticals Business Overview
  58. 8.10.3 Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  60. 8.10.5 Ionis Pharmaceuticals Recent Developments
  61. 8.11 Avet Pharmaceuticals
  62. 8.11.1 Avet Pharmaceuticals Company Information
  63. 8.11.2 Avet Pharmaceuticals Business Overview
  64. 8.11.3 Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  66. 8.11.5 Avet Pharmaceuticals Recent Developments
  67. 8.12 Alnylam Pharmaceuticals
  68. 8.12.1 Alnylam Pharmaceuticals Company Information
  69. 8.12.2 Alnylam Pharmaceuticals Business Overview
  70. 8.12.3 Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  72. 8.12.5 Alnylam Pharmaceuticals Recent Developments
  73. 8.13 Akcea Therapeutics
  74. 8.13.1 Akcea Therapeutics Company Information
  75. 8.13.2 Akcea Therapeutics Business Overview
  76. 8.13.3 Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  78. 8.13.5 Akcea Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Transthyretin Amyloid Cardiomyopathy Value Chain Analysis
  2. 9.1.1 Drugs for Transthyretin Amyloid Cardiomyopathy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Transthyretin Amyloid Cardiomyopathy Sales Mode & Process
  6. 9.2 Drugs for Transthyretin Amyloid Cardiomyopathy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Transthyretin Amyloid Cardiomyopathy Distributors
  9. 9.2.3 Drugs for Transthyretin Amyloid Cardiomyopathy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst